JAMA

Sutter Health and Charles R. Drew University Partner to Address Physician Shortage and Health Inequities Across California

Retrieved on: 
Wednesday, March 6, 2024

"This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.

Key Points: 
  • "This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.
  • Additionally, it will fund HEARE over the next five years to help accelerate interventions that address root causes of inequities.
  • Sutter Health and CDU will also explore additional opportunities to broaden the partnership and train more physicians with future initiatives.
  • This investment is part of Sutter’s broader commitment to address California’s growing physician shortage and persistent health inequities by enhancing access to culturally competent care for under-represented populations.

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

Mastercard Expands HealthLock Benefit to Millions of U.S. Cardholders, Enabling Automated Detection of Potential Medical Claims Errors, Overbilling and Fraud

Retrieved on: 
Tuesday, March 5, 2024

HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.

Key Points: 
  • HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.
  • As new claims come in, the platform analyzes and flags each one for potential errors, fraud or overbilling.
  • Data from the Journal of the American Medical Association shows medical overbilling, fraud and abuse cost Americans hundreds of billions of dollars annually1.
  • They will have access to HealthLock’s Medical Claims Monitor, which monitors and protects your medical data privacy against fraud, at no cost.

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

Retrieved on: 
Tuesday, March 5, 2024

To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.

Key Points: 
  • To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.
  • View the full release here: https://www.businesswire.com/news/home/20240305266724/en/
    Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes.
  • The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes.
  • This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer.

Addressing New York's Youth Mental Health Crisis, Montefiore Announces Plans for New Pediatric Inpatient Psychiatry Unit

Retrieved on: 
Wednesday, March 6, 2024

BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx. The Montefiore Einstein Center for Children's Mental Health of the Children's Hospital at Montefiore Einstein will be funded in part by a nearly $6 million appropriation to Montefiore spearheaded by New York State Assembly Speaker Carl Heastie and Assembly Member Michael Benedetto. The 21-bed child and adolescent unit will be located within the New York City Children's Center (NYCCC) campus adjacent to the Albert Einstein College of Medicine and will serve as a model for urban pediatric inpatient psychiatric services. The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region. The proposed center will be designed to provide best-in-class intensive treatment for youth with serious behavioral health conditions including severe depression, anxiety, trauma, suicidal thoughts, psychosis and other acute psychiatric conditions.

Key Points: 
  • BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx.
  • The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region.
  • As a leading health system in New York renowned for delivering exceptional care, I am confident that Montefiore will exceed in tackling mental health disparities with the new pediatric psychiatry unit," said New York State Assembly Speaker Carl Heastie.
  • The Montefiore pediatric psychiatry unit will provide 24/7 best-in-class care and access to comprehensive evaluation and care administered by mental health professionals expert in pediatric psychiatry.

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

Retrieved on: 
Thursday, February 8, 2024

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

Key Points: 
  • ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
  • Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc.  She was previously Titan’s Chief Scientific Officer and has been with the company since 2007.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board.
  • I look forward to working closely with the management team to bring BICX104 to market.”

Alberta’s new policies are not only anti-trans, they are anti-evidence

Retrieved on: 
Monday, February 5, 2024

Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.

Key Points: 
  • Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.
  • Smith has unveiled a suite of policies that directly attack trans and gender-diverse children and youth in Alberta.
  • As we explain below, these policies are at odds with research about gender-affirming care, curriculum and sports.

Evidence on trans-affirming care

  • Like all medicines, side effects are a risk but researchers caution against fear-mongering in response to gender-affirming care.
  • The evidence about trans-affirming health care for youth is clear — it saves lives.
  • Rather than restrict life-saving medical care, experts in fertility medicine call for increased accessibility for trans people to fertility services.

Sex education evidence

  • Classroom instruction on gender, sexuality and sexual orientation also now requires parental notification and opt-in.
  • Finally, third-party resource materials on gender, sexuality and sexual orientation in schools need to be pre-approved by the ministry to make sure they’re “age-appropriate.” Education experts agree that what is needed to protect youth — including cisgender and heterosexual kids — from potential abuse is robust and consent-based sexual health education.
  • Youth have the right to knowledge and skills about their bodies, consent, safe/unsafe touch and healthy relationships.

Risk of parental, peer rejection

  • This process essentially requires schools to “out” youth to their parents, who may reject their children.
  • Smith incorrectly suggests that parental rejection of 2SLGBTQIA+ kids is rare.
  • For those who experience family rejection, the rates of suicide are incredibly high.

Trans athletes evidence

  • Smith’s policy will also ban trans girls and women athletes from participating in competitive women’s sports.
  • Some scientists maintain that trans women and girls have no “biological advantage” over cisgender girls and women.
  • A book on the topic that reviewed evidence on testosterone determined there is no direct relation between the hormone and athletic performance.

What’s the truth?

  • In contrast, trans youth who are affirmed in schools, health care and in sports have better self-confidence and relationships with their parents.
  • Smith has incorrectly warned there are risks associated with affirmation and inclusion in schools for trans kids.
  • It includes more information on clinical guidelines for the prescription of puberty blockers for the purposes of gender-affirming care.


Corinne L. Mason receives funding from SSHRC. Leah Hamilton receives funding from SSHRC.

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Retrieved on: 
Friday, February 2, 2024

This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).

Key Points: 
  • This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).
  • At present, eight regulatory agencies have joined Project Orbis, including the FDA, the Australia Therapeutic Goods Administration (“TGA”), HSA, Health Canada (HC), the U.K.
  • Previously, two NDAs for toripalimab for the treatment of NPC had been submitted to the TGA through Project Orbis and were successfully accepted.
  • Junshi Biosciences will explore accelerated marketing opportunities in countries and regions where it is applicable.